What clinical trials might be relevant for Spindle Cell Sarcoma

Clinical Trials for Spindle Cell Sarcoma: What's Relevant for Marlo

Based on your documents and current medical guidelines, here are the clinical trial approaches that may be relevant for spindle cell sarcoma, particularly given Marlo's specific molecular findings:

EGFR-Targeted Trials (Most Relevant to Marlo)

Since Marlo's tumor carries an EGFR ITD (internal tandem duplication) and KDD (kinase domain duplication), trials focusing on EGFR-altered tumors are particularly important:

• Basket trials that enroll patients with EGFR mutations across multiple cancer types
• Trials testing irreversible pan-HER inhibitors (like afatinib) - your treatment strategy document specifically mentions this as a consideration
• Combination trials pairing EGFR inhibitors with MET inhibitors (addressing potential resistance pathways)

According to NCCN Soft Tissue Sarcoma Guidelines, targeted therapy approaches for sarcomas include multikinase inhibitors and tyrosine kinase inhibitors, though spindle cell sarcomas specifically may have limited trial options compared to more common subtypes.

---

Immunotherapy & CAR-T Trials

Your documents specifically mention:

St. Jude 3CAR / B7-H3 CAR-T Trial

• Your treatment strategy document flags this as worth investigating
• Important consideration: Your team correctly notes that CAR-T may have limited efficacy in "cold" tumors (tumors with minimal immune infiltration)
• Strategic question: Should immune-priming strategies (like the neoantigen vaccine you're exploring) come before CAR-T to convert the tumor microenvironment?

According to NCCN Guidelines, checkpoint inhibitors (anti-PD-1/PD-L1) have shown activity in some sarcoma subtypes, particularly those with high tumor mutational burden (TMB) or microsatellite instability (MSI-H).

---

ADC (Antibody-Drug Conjugate) Trials

Your strategy document mentions screening ~40 antibodies/ADCs through your organoid work. Relevant trial categories include:

• EGFR-targeting ADCs - directly relevant to Marlo's mutation
• General sarcoma ADC trials - testing novel conjugates in soft tissue sarcomas

---

Combination & Novel Approaches

Your documents explore several sophisticated strategies:

1. Afatinib + MET inhibitor combinations - your team is gathering evidence on this
2. Neoantigen vaccine + checkpoint inhibitors - converting cold tumors to hot
3. FAP-targeted radioligand therapy - your German centers research avenue
4. Radiation + systemic therapy combinations

---

How to Find Trials Specific to Marlo

Search strategies (as mentioned in your treatment document):

1. ClinicalTrials.gov searches:

   • "EGFR mutation" + "sarcoma"
   • "spindle cell sarcoma" + "pediatric"
   • "tyrosine kinase inhibitor" + "soft tissue sarcoma"
   • "CAR-T" + "solid tumor"

2. Specialty resources:

   • St. Jude Children's Research Hospital - contact trial coordinators directly (your document flags this)
   • NCI Pediatric Oncology - for pediatric-specific trials
   • Sarcoma Alliance for Research through Collaboration (SARC) - coordinates sarcoma trials

3. Basket trial platforms:

   • Trials enrolling based on molecular features (EGFR ITD/KDD) rather than cancer type alone

---

Key Questions to Ask Your Oncology Team

Based on your documents and the NCCN guidelines:

1. "Are there any open EGFR-targeted trials that would accept Marlo's specific mutation profile (ITD/KDD)?"

2. "Should we pursue immune-priming strategies (vaccine, checkpoint inhibitors) before considering CAR-T, given the 'cold' tumor phenotype?"

3. "What is the evidence for afatinib versus current therapy in EGFR-altered sarcomas, and are there trials testing this?"

4. "Are there trials combining targeted therapy with immunotherapy or radiation that might be appropriate?"

5. "What are the travel/logistics requirements for St. Jude enrollment, and what is the current enrollment status?"

6. "Given Marlo's age (7 years old), are there pediatric-specific trial designs we should prioritize?"

---

Important Context from Guidelines

According to NCCN Soft Tissue Sarcoma Guidelines (Version 1.2025), treatment of advanced sarcomas increasingly emphasizes:

• Molecular profiling-driven selection (which you're doing comprehensively)
• Combination strategies rather than single agents
• Early integration of immunotherapy in appropriate cases
• Participation in clinical trials when available, particularly for rare subtypes

Your strategy document's multi-pronged approach—combining organoid drug screening, molecular profiling, targeted therapy optimization, and vaccine development—aligns well with current best practices for precision oncology in rare pediatric sarcomas.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.